

UNDERSTANDING OF MALARIA AND ITS THERAPEUTIC REGIMENS – THE WAY FORWARD

ABSTRACT

Malaria is an ancient disease recognized by Hippocrates over 2413 years ago, caused by Plasmodium species, first identified by Charles-laveran 123 years ago affect 300 – 500 millions human worldwide, responsible for 3 deaths in every 30 seconds. The knowledge of classification, biology, pathology, pathogenesis, diagnosis and treatment of malaria is a tremendous achievement towards control of the disease. But complete elimination of malaria perhaps will still take another time, since a lot need to be known about the molecular biology of antigenic shift and drift, nature and mechanisms of action of the parasite toxin, in order to have basis for definite vaccine development. By so doing, radical cure and total eradication of malaria can be achieved.

Keywords; Malaria, Hippocrate, Laveran, antigenic shift, radical care, eradication.

1.0 INTRODUCTION

Malaria is an infectious disease caused by a protozoan of the phylum: *Apicomplexa*, class: *Sporozoea*, subclass: *Coccidia*, suborder: *Haemosporina*, family: *Plasmodidae*, genus *Plasmodium* and transmitted by the female mosquito of the genus *Anopheles* when it feeds by sucking human blood and whose life cycle alternates between man and mosquito.^[1] An anopheline mosquito inoculates plasmodium sporozoites to initiate human infection. Circulating sporozoites rapidly invade liver cells. Exoerythrocytic stage tissue schizonts mature in the liver and invade erythrocytes. Only erythrocytic parasites cause clinical illness. Repeated cycles of infection can lead to the infection of many erythrocytes and serious disease. Sexual stage gametocytes also develop in erythrocytes before taken by mosquitoes where they develop into infective sporozoites^[2,3]. The means of infection are through infective mosquito bites, contaminated syringes and vertical transmission from mother to foetus through placenta^[4,5]. Malnutrition, splenomegaly, and anaemia are the expected complications of repeated attacks of malaria^[1,2].

The emergence of resistant malaria in addition to the toxicity of drugs currently used as anti-malarials has created a major concern and an urgent need for development of new anti-malarial agents. Throughout the world, herbs have sustained man not only as source of food but also as medicines utilized in various ways for varied purpose. In the last decade, people have become increasingly aware of the use of medicinal plants for the treatment of diseases ^[6]. In developing countries, it is important to know the therapeutic potentials of substances from natural sources, since local drugs could be of great value and substitute for the more sophisticated and expensive drugs. Therefore, there is need to find cheaper and pharmacologically active substances from natural products and this has defined the research goals of developing nations as encouraged and recommended by the World Health Organization ^[7].

Traditional healers have made various efforts to control diseases including malaria-using herbs. Few of these plants have been properly identified and documented. Only a very small percentage of the plants with ethnopharmaceutical potentials have been subjected to scientific analysis hence their safety and efficacy are questionable ^[8]. World Health Organization (WHO) in recognition of the increased value of herbal medicine in primary health care, especially in developing countries has advocated for the proper identification, sustainable exploitation, scientific development and appropriate utilization of herbal medicines, which provide safe and effective remedies in medicine ^[9]. Investigation on the risks associated with prolonged and improper use of some herbal drugs revealed a potential for toxic and teratogenic effects in biosystem ^[10], yet scientific information and the results of comparative studies are scarce on the effectiveness and safety of most traditional remedies and techniques ^[11]. Of the estimated 300,000 plants species acclaimed worldwide as possible pharmaceutical candidates, only about 5% have been investigated scientifically for medicinal properties ^[8].

1.1 JUSTIFICATION

Malaria is the worst human problem at the moment. There were an estimated 247 million malaria cases among 3.3 billion people at risk in 2006, causing nearly a million deaths, mostly children under 5 years and 109 countries were endemic for malaria in 2008, but 45 countries are within African region. More than 1 reported cases per 1000 population per year was reported in 2006. Nigeria accounts for a quarter of all malaria cases in the

66 African region and almost all cases are caused by *P. falciparum* with recorded 57,506,430
 67 malaria cases and 225,424 deaths in 2006. In 2007, Nigeria was the 7th malaria country.
 68 Treatment is one of the recommended policies and strategies for malaria control ^[12]. The
 69 disease causes wide spread death and suffering, imposes financial hardship on poor
 70 household, holds economic growth and improvement in living standard ^[13]. Between 10 and
 71 13% of maternal deaths are caused by malaria in endemic countries and spontaneous
 72 abortions are reported in up to 60% of maternal malaria cases ^[14]. The rapid spread of
 73 resistance to antimalarial drugs present a potentially devastating threat to effective, safe
 74 and affordable treatment. Chloroquine was the main drug used for decades, but increasing
 75 resistance forced its replacement with other antimalarial drugs ^[13], 40 – 60% of malaria
 76 cases in Nigeria have been reported not to respond to treatment with the drug ^[15]. Toxicity
 77 of antimalarial drugs and lack of vaccine against malaria have compounded problems in
 78 malaria chemotherapy ^[15]. While large number of people in the rural areas of developing
 79 countries still consume crude decoctions and concoctions of medicinal herbs ^[16]. Scientific
 80 and technological advances in the field of chemotherapy will boost malaria control ^[17].

81 Since prehistoric times, plants based medicines have been in use for treatment of
 82 diseases until synthetic drugs were developed in the 19th century. Today the use of herbs
 83 continue to exist throughout the developing world, while 40% of prescription drugs are still
 84 herb based remedies for treatment of illnesses ^[18, 19]. Phytochemicals are protective,
 85 disease preventing plant substances ^[20]. Natural products in several developing countries
 86 are still the mainstay of all medicines ^[21]. The most commonly used sources of drugs are
 87 herbs, plant extracts, seeds, leaves, barks of certain plants, tubers and roots. Noteworthy in
 88 this regard is the use of single remedy or plant extract to treat more than one disease and
 89 combination of various plants extracts for broad-spectrum therapy. Within the context of
 90 traditional practice, decoctions or infusions of plants have been used commonly to treat
 91 malaria and malaria symptoms. There are numerous illustrations of plant based antimalaria
 92 drugs. Quinine is an important drug of plant origin with history of long use. This alkaloid
 93 occurs naturally in the bark of *Cinchona* tree, and is used in the treatment of malaria apart
 94 from its use to relieve nocturnal leg cramps ^[22]. *Artemisia annua* has been in use for more
 95 than 2000 years and is found effective in the treatment of malaria ^[23]. The plant,
 96 *Azadirachta indica* has been used extensively for malaria treatment in Nigeria and was
 97 proven to have antimalarial activity ^[24]. Other plants that have been used include; *Sida*

acuta, *Carica papaya*, *Vernonia amygdalina*, *Khaya senegalensis*, *Nuclea latifolia*, *Anacardium occidentale*, *Mangifera indica*, *Scleocarya birrea*, *Spondia mombin*, *Balanites aegyptica*, *Newboldia laevis*, *Commiphora kerstingii*, *Allium sativum*, *Tridilia emetica*, *Phoenix dactylifera*, *Piper guinense*, *Neocarya macrophylla* ^[25], *Achillea millefolium*, *Baccaris trimera*, *Lippia alba*, *Matricaria chamomilla*, *Mikania glomerata*, *Tanacetum pathenium* ^[25], *Duguetia furfuracea*, *Xylopia emarginata* ^[27], *Centella asiatica* ^[28], *Bupleurum montanum*, *Bupleurum plantagineum* ^[29], *Ferula opoda* ^[30], *Cynodon dactylon* ^[30], *Setaria magaphylla* ^[32], *Momordica foetida* ^[33], *Momordica charantia*, *Curcubita maxima* ^[34], *Phyllanthus amarus* and *Phyllanthus niruri* ^[35]. Tropical plants that are used for the treatment of malaria in over 100 underdeveloped and developed countries of the world are provided in table 1.

Many plant genera were found to be used either alone or in combination with each other for the treatment of malaria. The plants are mainly of the families *Rubiaceae* and *Apocynaceae* and a few from the families *Bombaceae*, *Loganaceae*, *Rutaceae*, *Solanaceae*, *Meliaceae* and *Gramniae*. Plants used for malaria medicines vary enormously from one community to the other, in both the choice of plant and methods of preparations. Complementary to oral therapy is steam treatment, where the patient is covered with a thick blanket or cloth and subjected to the vapours from a steaming pot of herbs (ingredient of this hot pot include the leaves of lemon grass, paw-paw, mango, and guava). Sometimes the leaves of these plants are used for the preparation of “teas” typical teas are made from lemon grass (*Cymbopogon citratus*), lime (*Citrus aurantifolia*) and sometimes guava leaves. This form of treatment is recommended usually for mild attacks of malaria ^[16]. Coker and Adesegun compiled a list of over 200 medicinal plants claimed by traditional healers and communities to have antimalarial activity^[36].

In spite of several pitfalls encountered in the medicinal plant research, the prospects of developing indigenous drugs for health care delivery systems should be viewed positively ^[37, 38]. In a broader perspective, plants are economic source of a number of important drugs such as morphine, atropine and digoxin. The perpetual biodiversity in nature will continue to provide newer species of plants for production of newer drugs. However, species of plants yielding better quantity of the desired chemicals such as active principles can be developed through genetic engineering while their production can be accelerated through tissue culture techniques ^[37]. The objective of producing affordable, potent and safer drugs from plants can be met to certain extent by promoting formulations of medicines in their

natural or semi-processed form (powder or extracts) from plants as used in traditional medicine for some disorders. Standardization especially in respect of dosages will be necessary through controlled clinical trials to prove their efficacy and safety^[39]. Research on medicinal plants need to be conducted across all geographical regions of the world, this will highlight the effect of climate, soil chemistry and other environmental factors on the quality of the plant products^[39, 40]. The Nupe ethnic group from Bida emirate have been using *Abrus precatorius* leaf for the treatment of both acute and chronic malarial symptoms. The use of *Abrus* leaf in the treatment of malaria among Nupes is sometimes either the last option after drugs have failed or due to poverty^[41]. High cost, increased toxicity level and emergence of parasites resistant to antimalarial drugs (e.g. chloroquine) have made eradication of malaria by chemotherapy difficult and threatened to render current antimalarials obsolete^[42].

2.1 HISTORICAL BACKGROUND OF MALARIA

Human malaria has been recognized since the earliest period, and the occurrence of mosquitoes trapped in amber suggests its prevalence in prehistoric times^[43]. Malaria is an ancient disease recognized by Hippocrates about 400 BC. He described the three characteristic stages of malaria attack as chills, high fever and profuse sweating^[44]. The first evidence that *plasmodium* was the aetiologic agent of malaria was recognized by Charles Laveran in 1890 as he scanned a live mount of a febrile soldiers blood at Constantine University Hospital in Algeria^[45]. Laveran noted pigment granule containing red blood cells in various forms of elongated or crescents shape disfigurement. Translucent round cells with pigmented granules were also seen, and most notably, amoeboid-like cells possess long whipping strands that dramatically interacted with and were capable of “drawing in” neighbouring red blood cells. Laveran understood that he was looking at the malaria pathogen and this observation stands as a singular historical event in providing support for a protozoan basis of disease. Twenty years later, MacCallum^[46, 47] described exflagellation the whipping motions of the sinuous flagella as the extrusion of male gametes after emergence from within red blood cells a process, which occurred in the gut of the mosquito vector^[48, 49]. A variety of names were used to describe the disease and they include the shakes, march, noman, jungle, intermittent fever, ague and chills^[50]. The work of Laveran, Ross, MacCallum^[45 - 49], and some other malariologists^[50] showed the occurrence of

developmental cycle in the blood corpuscles and the transmission through mosquitoes. By the early part of the last century, it was believed generally that the broad outlines of the life cycle was known fully, with sporozoites injected by a mosquito bite, thought to enter the cells directly and undergo schizogony. However the actual penetration of a corpuscle was described by Schaudin ^[44] who observed that sporozoites, on entering the blood did not directly enter red blood cells as formerly thought but within half an hour were carried to reticuloendothelial system (usually, the liver) where they underwent a schizogony circle ^[43].

2.2 MALARIAL GLOBAL SITUATION

According to World Health Organization (WHO), each year 300 to 500 million people living in the tropics and subtropics are infected with malaria parasites with nearly 3 million (mostly children) dying ^[51]. About 1.5 billion people are known to live in the regions where malaria is endemic. The regions are central and northern South America, tropical Africa, North Africa including the Nile valley, parts of Middle East, Central Indian Subcontinents and South East Asia excluding Hong Kong and Macao and East Indies. Malaria is imported into the United Kingdom with 1500 – 2000 cases reported each year, and 10 – 20 death. Approximately three-quarters of reported malaria cases in the UK are caused by plasmodium falciparum ^[52]. About 93% of the 550 million people living in Africa are at risk of malaria and over 90% of the 300-500 million clinical cases reported from Africa ^[53]. Malaria occurs in 100 countries with about 40% of the world's population at risk ^[54]. Malaria epidemics are on the increase due to fabricated conflicts and climate associated disasters causing the movement of non-immune populations to malaria endemic areas ^[55]. Urban and periurban malaria are now substantial problems in certain areas of Asia and Africa. Malaria is becoming more difficult to manage because of multi-drug resistance since effective drugs are unavailable ^[56]. Malaria is directly responsible for one in five childhood deaths in Africa and its resurgence in Africa contrasts dramatically with the global decline in mortality since 1900 ^[13]. Nigeria accounts for a quarter of all malarial cases in the WHO African region. Transmission in the south occurs all-year round and is more seasonal in the north ^[12]. In Nigeria malaria affects more people than it did in the 1960s ^[57]. Fifty percent (50%) of Nigerian population experience at least one episode of malaria every year. The Federal Ministry of Health reported that one in four people suffer from malaria at one time or the other ^[2]. Transmission in tropical countries is highly heterogenous spatially and

seasonally. *Plasmodium falciparum* is known to cause the majority of severe clinical disease^[59].

About 110 million Nigerians are at risk of infection from malaria parasites ^[58] and malaria is responsible for deaths before the age of 5 years in 1/5 and 1/3 of children in urban and rural areas respectively ^[60]. In Nigeria and probably and other parts of West Africa, the predominant parasite is *Plasmodium falciparum* (75%). Others are *Plasmodium malariae* (15%) and *Plasmodium ovale* (3%) with *Plasmodium vivax* probably not found in West Africa (James and Gilles, 1985). Funding for malaria control in Nigeria was increased from US\$ 17 million in 2005 to US\$ 60 million in 2007, provided by the government, the Global Fund and the World Bank ^[12].

2.3 CLASSIFICATION OF MALARIA

Malaria fever has been categorized as benign, simple or tertian (caused by *Plasmodium vivax*) or aestivo-autumnal, malignant tertian, pernicious quotidian, subtertian or tropical (caused by *Plasmodium falciparum*) or quartan ague or quartan malaria (caused by *Plasmodium malariae*) or ovale tertian malaria (caused by *Plasmodium ovale*). *Plasmodium vivax* shows the widest distribution, being prevalent throughout the tropics and many temperate regions and characterized by relapses: reappearances of symptoms after a latent period of up to 5 years, as is infection with *Plasmodium ovale*, which occurs chiefly in tropical Africa. Such relapses are due to the sudden activation of hypnozoites (sleeping merozoites) in liver cells. *Plasmodium malariae* is much less common than *Plasmodium vivax* and *Plasmodium falciparum*. Although falciparum malaria and malariae malaria do not show relapses, they are subjected to 'recrudescence' repeated manifestation of infection after a relatively short latent period between 3 months and 1 year^[43]. Malaria genetics reveal many peculiarities. There is immunity amongst Africans living in endemic areas that are exposed to repeated reinfection (premonition). There are racial differences in susceptibility; and resistance is associated with certain genetic factors; e.g. haemoglobin S, which is common amongst Africans with sickle cell anaemia trait with lethal effect. Nevertheless, confers resistance to falciparum malaria, just as in those whose erythrocytes are deficient in glucose-6-phosphate dehydrogenase enzyme ^[2]. The means of infection are through infective mosquito bites, contaminated syringes and vertical transmission from mother to fetus through placenta ^[5].

2.4 BIOLOGY OF MALARIA PARASITES

The plasmodium life cycle is complex with a number of different forms that differ in microscopic appearance and antigenicity. In the human host, sporozoites, the infectious form injected by the mosquito, are carried by the blood stream to the liver, where they infect liver cells. In these cells, each parasite enlarges and subdivides, producing thousands of merozoites, which are then released into the bloodstream and establish the cycle involving the erythrocytes. The parasite grows and divides in the erythrocytes of the host. The earliest form resembles a ring, with a large pale food vacuole in the central area, with the nucleus and cytoplasm being pushed to the periphery. This develops into a larger motile trophozoites, which goes on to subdivide, producing a schizont. The infected erythrocytes then break open, and the offspring of the division called merozoites (6 – 32) which after 5 – 16 days, months or years^[61] are released into the plasma. The duration of this cycle varies with species of plasmodium, *P. falciparum* (6 days), *P. ovale* (9 days), *P. vivax* (8 days) and *P. malariae* (14 days). The merozoites then enter new erythrocytes and multiply, repeating the cycle. The erythrocytic cycle takes 2 days for *P. falciparum*, *P. vivax* and *P. ovale* and 3 days for *P. malariae*. The attack of fever occurs at the rupture of the erythrocytes and release of the merozoites^[60]. The symptoms last for 12 to 24 hours^[62]. Some merozoites that enter erythrocytes develop into gametocytes, which are specialized sexual forms. Male and female gametocytes transform into about half dozen tiny whip-like gametes that swim about until they unite with the female gamete. The resulting zygote transforms into a motile form that burrows into the wall of the midgut of the mosquito and forms a cyst, which enlarges as diploid nucleus that undergoes meiosis, dividing asexually into numerous offspring. The cyst then ruptures into the body cavity of the mosquito, and the released sporozoites find their way to the mosquito's salivary gland and saliva, from which they must be injected into a new human host^[63, 64]. The incubation period for malaria is between 10 – 35 days^[61]. Mosquito is the definitive host. The only function of human is to enable the parasites infect more mosquitoes, so that further sexual recombination can occur. Asexual cycle takes place in man while sexual cycle takes place in mosquito^[65]. Although malaria can be transmitted by transfusion of infected blood, congenitally, and by sharing needles, infection usually is transmitted by the bite of infected female Anopheline mosquitoes. Once the tissue schizonts burst in *P. falciparum* and *P. malariae* infections, no forms of the

parasite remain in the liver. However, in *P. vivax* and *P. ovale* infections, tissue parasites (hypnozoites) persist that can produce relapses of erythrocytic infection months to years after the primary attack. Once plasmodia enter the erythrocytic cycle, they cannot reinvade the liver; thus, there is not tissue stage of infection for malaria contracted by transfusion. The merozoites invade more erythrocytes to continue the cycle, which proceeds until death of the host or modulation by drugs or acquired partial immunity. For erythrocyte invasion, merozoites bind to specific ligands on the red cell surface ^[66]. *P. falciparum* has a family of binding proteins that can recognize a number of host cell molecules, including glycophorins A, B, and C, as well as band 3. It is able to invade all stages of erythrocytes and therefore can achieve high parasitemias, *P. vivax* is more selective in its binding; it needs to recognize the Duffy chemokine receptor protein as well as reticulocyte-specific proteins; thus, it will not establish infection in Duffy-negative individuals and will only invade reticulocytes. Because of this restricted subpopulation of suitable erythrocytes, *P. vivax* rarely exceeds 1% parasitaemia in the bloodstream. *P. ovale* is similar to *P. vivax* in its predilection for young red blood cells, but the mechanism of its erythrocyte recognition is unknown. *P. malariae* recognizes only senescent red cells, maintains a very low parasitemia, and typically cause an indolent infection ^[67]. *P. falciparum* assembles cytoadherence proteins (the PfEMPs encoded by a highly variable family of var genes) into structures called knobs on the erythrocyte surface. This allows the parasitized erythrocyte to bind to the vascular endothelium, to avoid the spleen, and to grow in a lower oxygen environment. For the patient, the consequences are microvascular blockage in the brain and organ beds and local release of cytokines and direct vascular mediators such as nitric oxide, leading to cerebral malaria ^[68].

2.5 PATHOGENESIS OF MALARIA

Plasmodium falciparum is not only the most common in Africa but also is the most virulent and enjoys the reputation as the greatest killer of mankind being particularly dangerous to children ^[2] and responsible for all severe complications and deaths ^[3]. Infective female Anopheles mosquito injects saliva containing plasmodia sporozoites, which enter the parenchyma cells of the liver usually within 1 hour ^[1]. The merozoites rupture out from the liver into blood stream and invade erythrocytes ^[69]. Each species has a specific receptor on erythrocytes it attaches. For example *Plasmodium vivax* attaches to the duffy blood group antigen and many natives of West Africa lack this antigen and therefore are

resistant to *Plasmodium vivax*^[70]. The infections in the millions of different red blood cells nearly become synchronous, rupture and release daughter protozoa at the same time. For *P. malariae* the cycle takes 72 hours so that fever appears every third day^[64]. In other species of plasmodia, rupture occurs every 48 hour. The liberated merozoites rapidly infect a new population of erythrocytes initiating the next cycle of fever and chills^[70]. The merozoites enter red cells and differentiate into male and female gametocytes, which are ingested by blood sucking female Anopheles mosquito. *Plasmodium vivax*, *Plasmodium malariae* and *P. ovale* parasitaemia are of relatively low grade because the parasites favour either young or old red cells; *Plasmodium falciparum* invades red cells of all ages including the erythropoietic stem cells in bone marrow, so parasitaemia may be very high^[69]. *Plasmodium vivax* and *Plasmodium ovale* prefer young red cells and *Plasmodium malariae* prefer aged red cells. *Plasmodium falciparum* has no secondary phase and the infection is resolved in 3 years (usually within 1 year)^[70]. *Plasmodium malariae* had occurred as long as 10-53 years in the infected humans after initial exposure especially after splenectomy. The spleen appears to be involved in the prevention of maturation of parasites thereby preventing reinfection^[71]. *Plasmodium malariae* with its prolonged latency is the most common cause of transfusion malaria in non-endemic areas, whereas *Plasmodium falciparum* and *Plasmodium vivax* are the most common cause of malaria worldwide^[70]. Patients with malaria often exhibit laboratory abnormalities due to an acute phase response. Lipid profile changes are characteristic for malaria^[72]. Changes in high-density lipoprotein and very low-density lipoprotein in human serum are related to lipid metabolism of plasmodium vivax^[73].

2.6 PATHOLOGY OF MALARIA

The most characteristic symptom of malaria is the occurrence of paroxysm of fever with temperatures of up to 40-41°C at regular intervals-every 48 hours (*Plasmodium falciparum*, *Plasmodium ovale* and *Plasmodium vivax*) or 72 hours (*Plasmodium malariae*) tertian or quartern fever – alternating with good periods of no fever^[2, 74]. The periodicity of parasitaemia and febrile manifestation is preceded by headache, lassitude, loss of appetite, muscle pain and chills, resulting in violent uncontrollable shivering with teeth chattering, accompanied by thirst, nausea, vomiting and in severe cases sometimes by delirium and convulsion in children frequently ending in death. These signs are more pronounced usually

in falciparum malaria ^[2]. Malaria was perceived as the world's worst health problem ^[75]. More people are dying each year from malaria than 30 years ago and malaria is returning to areas from where they had been eradicated. High level of malaria parasitaemia has been observed in African children with symptomatic HIV infection. These children have been found to be protected against cerebral malaria and invariably deaths due to cerebral malaria. This has been attributed to lower levels of tumor necrosis factor, which boost antibodies against malaria in HIV infected children ^[76 - 78].

Malnutrition, splenomegaly and anaemia are the expected complications of repeated attacks of malaria. However, acute falciparum malaria produces complications collectively known as pernicious or malignant malaria. This arises from interruption of blood flow in the capillaries that interferes with oxygen supply causing anoxia and may eventually lead to rupture of the capillaries and bleeding into the tissues, invariably resulting in death ^[1, 2]. There are two main types of pernicious malaria: cerebral malaria, which causes brain damage resulting from the clogging of the brain capillaries with symptoms as severe headache, convulsions, delirium and other psychotic signs with temperature rising up to 42°C. Cerebral malaria frequently ends in death and is the most lethal of all the malaria. The other is agid malaria, involving other organs of the viscera: the signs in the patients are cold clammy skin, with high internal temperature as well as severe vomiting, diarrhea and sweating. The consequences are never as severe as in cerebral malaria, but extreme exhaustion may lead to prostration and unconsciousness ^[2].

2.7 DIAGNOSIS OF MALARIA

Malaria is a disease of many facets with symptoms that trigger most of the diseases of man. Jeffery ^[79] divides the parasitaemia of man into four phases: preclinical, clinical, terminal (asymptomatic), and relapse (asymptomatic and symptomatic). Bray ^[80] designated another prior to the preclinical as the pre-erythrocyte phase, which lasts only 24 hours, as a period of cytoplasm fission of a multinucleate mass. Preclinical period follows the appearance of the parasite in the peripheral blood and which is the time when frank manifestations appear. Periods of chill alternating with longer febrile intervals are the classical manifestations ^[81].

Malaria parasites in blood sample stored at 4°C are viable for at least a period of one week. *Plasmodium falciparum* can remain viable for a period of 2 weeks ^[71]. A definite

diagnosis of malaria infection is established on the finding of parasites in the blood. Malaria should be suspected in all cases of fever in endemic areas or in persons who have been exposed to the infection. Microscopically diagnosis is only as reliable as the competence of the workers who prepare the blood slides and examine such slides. Diagnosis of human malaria is mainly by the detection of plasmodium species from microscopic examination of the blood. One should remember that the presence of malaria parasites in the blood is a sign of infection but not necessarily a cause of the disease ^[54, 59]. Although various modern methods ranging from density high-speedcentrifugation, with monoclonal antibodies to the application of magnetic separation techniques, DNA probes and even the newer amplification technique such as the polymerase chain reaction (PCR) have been tried, in order to detect scanty parasitaemias. It appears that the time honoured thin-and thick film blood examination by a competent microscopist remains unchallenged when it comes to simplicity and convenience ^[59].

Malaria rapid diagnostic tests (RDTs) are qualitative immune-chromatographic lateral flow tests in dipstick (strip), cassette or card form that detect malaria antigen in peripheral blood. Malaria antigen from a lyzed blood sample is reacted with anti-malarial monoclonal antibody conjugated to colloidal gold (pink-mauve) particles. The antigen-antibody colloidal gold complex migrates along the nitrocellulose membrane where it becomes bound (capture) by a line of specific monoclonal antibody, producing a pink line in the test result area. The line can be seen after a washing buffer has removed the background haemoglobin. A further pink line, i.e. inbuilt positive control, is produced above the test line indicating that the test reagents have migrated satisfactorily (it is not a malaria antigen control) ^[58].

Radioimmunoassays have also been tried for malaria diagnosis. Antibodies to malaria can be detected using enzymatic immunoassays or immune-fluorescence techniques. The antibodies to the asexual blood stages appear days to weeks after the infection and may persist for months. Although useful in survey work or for screening blood donors and reducing wastage, they are of little value in the “acute” malarial situation ^[54].

Solid-phase inhibition radioimmunoassays have been used to demonstrate parasite antigens. These assays use solubilized erythrocytes infected with *P. falciparum* and are based on the ability of washed infected red blood cells to inhibit the binding capability of radio-or enzyme-labelled antibody on a plastic of microtitre plate precoated with crude

extracts of malaria antigen obtained from *in-vitro* cultures of *P. falciparum*. Such test systems are useful where low parasitaemias in the range 5-50 asexual parasites/ μ l of blood are found. An inhibition radioimmunoassay test based on a monoclonal antibody labeled with a radioisotope, iodine -125, and used in an antibody 'sandwich', has also been described. In field trials it produced a detection level of > 1 asexual parasites of *P. falciparum*/ μ l of blood; better than one would expect from routine light microscopy^[54].

Serological methods of diagnosis of malaria have become of practical value since 1962 when the indirect fluorescent antibody test (IFAT) was introduced. In the IFAT procedure the antigen consists of a film of infected blood on a microscope slide. The slide is covered first with one of the serial dilutions of the test serum; then it receives a solution of antihuman globulin labeled with fluorescein isothiocyanate; after washing and drying, the slides are examined in a fluorescence microscope. Antibody in the test serum reacts with antigen of the malaria parasites and the antiglobulin reaction with the antibody is indicated by the fluorescence of the parasites. Fluorescence of the last serial dilution is given as a 'titre' of the antibody present^[54].

In recent years a number of new techniques based on the "dipstick" format, have become available for the diagnosis of malaria. These include the ICT-Malaria PF, OptiMALr and the Kat-Quick kits. The methods are based on the principle of the detection on plasmodial histidine rich protein-2 (HRP-2) or parasite-specificities lactate dehydrogenase (PLDH) which is present in *P. falciparum* and other Plasmodial infections. A number of reports claim sensitivities and specificities approaching 100% while other reports have claimed up to 6% cross reactivity with sera positive for rheumatoid factor. Some of these "dipstick" methods have been extended to include screening for other forms of malaria but to date results have not been quite impressive^[58].

Dipstick tests have the potential of enhancing the speed and also the accuracy of diagnosing *P. falciparum*, particularly in non specialized laboratories where inexperienced or junior staff may be involved, since very little training is required for these techniques. A potential problem with these methods is that the circulating antigen may be detected for many days up to 2 weeks in a laboratory after the elimination of viable parasites from the circulation. It must therefore be remembered that a positive test may not always be due to an active infection. The dipstick methods should be regarded as useful additional tests to

the long established diagnostic method of examining thick and thin blood films regarded as the standard, not as replacement methods ^[58].

Molecular biological detection tests have also been used for diagnosis and are known to use DNA and RNA probes. DNA probe is based on principle of hybridization with two complementary strands of the DNA helix separated (denatured) by chemical means, or heat treatment. The separated strands of DNA are then put into contact with a DNA probe. This probe has been obtained using recombinant DNA techniques, or produced synthetically. Most of the available DNA probes are specific to *P. falciparum* and sensitivities as low as 5 asexual parasites/ μ l of blood have been reported, but unfortunately, these results have only so far been obtained with radioisotopic method using iodine 125 or phosphorus 32. Enzyme-based systems with biotin and others are rather less sensitive although new probes specifically designed for enzymes detection may improve these levels considerably ^[54].

Ribonucleic acid (RNA) probes have also been evaluated with promising results. Unfortunately, RNA is less stable and cross-species reactivity could occur. RNA probes have been developed for all four human malarias and show an increased sensitivity due to the high number of target sequences which occur in RNA. Detection techniques using 12-hour autoradiography exposure have reportedly produced detection levels as low as few parasites/ μ l of blood. No effective non-radioactive label has yet been reported ^[54].

Other methods of diagnosis include the QBC II, Becton-Dickinson's Quantitative Buffy Coat (QBC) method. This involves centrifuging the patient's blood in special capillary tubes precoated with Acridine Orange (AO) in which parasite DNA is stained with AO. A small precision moulded plastic float presses the parasitized red cells (which occupy the upper most part of the red column) against the wall of the tube, where they can be viewed by ultra violet light microscopy. The sensitivity of this method is claimed to be very high with experienced users, although some reports suggest that young trophozoites of *P. falciparum* and *P. vivax*, could not be distinguished with any degree of certainty and that confirmatory blood films should always be examined. Additionally special equipment is required, which may preclude the method from being used in smaller centres ^[54].

Another relatively new method is the polymerase chain reaction (PCR) which uses a non-isotopically labeled probe following PCR amplification. It is possible to detect less than 10 parasites in over 10 μ l of blood. PCR may yet prove to be a valuable addition to the

examination of blood films for the diagnosis and speciation of malaria. Again, the special equipment required precludes all but the larger centre. Some researchers have claimed that PCR (and ELISA) techniques are as sensitive as blood films, however they are infinitely more expensive, require specialized equipment and take a longer time to complete ^[59].

2.8.0 TREATMENT OF MALARIA

Malaria is the classical example of a disease that affects the productivity of individuals, families and the entire world due to morbidity and mortality ^[82]. The first antimalarial drug was quinine isolated from the bark of cinchona specie (Rubiaceae) in 1820. In 1940, chloroquine was synthesized and until recently was the only drug used for the treatment of malaria. Chloroquine resistant *P. falciparum* is treated with alternative drugs or drugs combinations, which are expensive and sometimes toxic ^[83]. Chloroquine and hydroxychloroquine have been proven to have antiretroviral activity both *in-vivo* and *invitro* hence could be used to treat co-infection of malaria and HIV ^[84]. Mechanism of action of chloroquine remains controversial, the agent probably acts by concentrating in parasite food vacuoles, preventing the polymerization of the haemoglobin break down product, haemozoin and thus eliciting parasite toxicity due to the abundance of free haem. Resistance in *Plasmodium falciparum* has been attributed to mutations in a putative transporter PFCRT, however the clinical value of resistance-reversing drugs is not established. Chloroquine remains the drug of choice for the treatment of sensitive *P. falciparum* and other species of human malaria parasites. It rapidly terminates fever (in 24-48 hours) and clears parasitaemia (in 48-72 hours) caused by sensitive parasites. It is safe, cheap and many partially immuned individuals respond to chloroquine treatment ^[3]. Artemisinin and its derivatives are effective against drug-resistant *Plasmodium falciparum* and so they are of utmost important in the current antimalarial campaign ^[82] Artemisinin or Qinghaosu is a sesquiterpene lactone endoperoxide isolated from Chinese herb *Artemisia annua* L. (Asteraceae) that has been in use in traditional treatment for chills and fevers for more than 2000 years ^[85]. Artemisinin was isolated pure in 1972 and its structure was determined in 1979 ^[86]. Quick reduction of fevers, fast clearing of parasites from blood (90% of malaria patients recovered within 48 hours) are characteristics of artemisinin. WHO recommended that all countries experiencing resistance to conventional monotherapies should use combinations containing artemisinin derivative (artesunate) ^[81] and other agents

such as amodiaquine and fansidar^[86]. Lapdap that contains chloroguanol hydrochloride and dapson is one of the safest antimalarials in use^[87]. Terkuile *et al.* strongly recommended household level treatment for presumed malaria^[88].

Fansidar® may be used against chloroquine-resistant and presumptive falciparum malaria. A number of antibiotics in addition to the folate antagonists and sulphonamides are modestly active antimalarials but their mechanisms of action are unclear^[3, 88]. The sulphadoxin/pyrimethamine combination had been used to treat uncomplicated falciparum malaria for more than 30years. Non-silent mutations in dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes are responsible for the resistance to pyrimethamine and sulphadoxine respectively^[73]. The discovery of techniques for continuous maintenance of human *Plasmodium falciparum* *in vitro* has led to practical assays of susceptibility of these organisms to antimalarial drugs^[90]. The biology of malaria infection must be appreciated for understanding of action and therapeutic uses of antimalarial drugs^[42].

Malaria is the most important of the transmissible diseases. The incubation period of malaria is 10-35 days and since there are no effective drugs against sporozoites, infection with the malaria parasite cannot be prevented. Sporozoites develop into merozoites after 5-16 days and after months or years are released from liver into circulation. But *Plasmodium falciparum* has persistent hepatic circle. Primaquine, proguanil and tetracyclines (tissue schizonticides) act on this site and are used for radical cure. Chloroquine, quinine, mefloquine, halofantrine, proguanil, pyrimethamine and tetracyclines kill these asexual forms. These drugs are used to treat and prevent acute attacks called suppressive prophylaxis. Quinine, mefloquine, chloroquine, artesunate, artemether and primaquine (gametocides) prevent the transmission of infection^[62]. But artemisinin combination therapy (ACT) is currently being used as the first line therapy for falciparum malaria^[73].

2.8.1 CLASSIFICATION OF DRUG TYPES USED IN TREATMENT OF MALARIA

The drugs which are effective in the treatment of malaria may be divided into two groups; drugs which act on the asexual stage of the malarial parasite in the blood-quinine, chloroquine, proguanil, halofantrine, mefloquine and pyrimethamine and drugs which act on the exo-erythrocyte stage in the liver and gametocytes-primaquine. Doxycycline is effective against resistant *P. falciparum* and has been used with success in the far East. It should be taken after meals with copious fluids. There are two ways in which malaria can be

attacked by drugs-chemosuppressive and treatment of established disease. Suppressive treatment means the regular administration of a drug to prevent the clinical manifestation of the disease. The best drug for this purpose varies in different parts of the world. *P. falciparum* strains from many parts of the world are resistant to one or more antimalarial drug^[91]. Drugs for prevention of malaria include chloroquine (500mg weekly), mefloquine (250mg weekly), doxycycline (100mg daily), malarone 1 tablet (250mg atovaquone/100mg proguanil) daily, primaquine 26.3mg (15mg base) daily for 14 days and proguanil (200mg daily) as an alternative to mefloquine. Drugs that eliminate developing or dormant liver forms are called tissue schizonticides (e.g. primaquine and tafenoquine), those that act on erythrocytic parasites are blood schizonticides (e.g. quinine, chloroquine, halofantrine, arteflene, artesunate) and those that kill sexual stages and prevent transmission to mosquitoes are gametocides (e.g. primaquine, chloroquine, quinine). No one available agent can reliably effect a radical cure that is eliminate both hepatic and erythrocytic stages. Few available agents are causal prophylactic drugs that are capable of preventing erythrocytic infection. All effective chemoprophylactic agents kill erythrocytic parasites before they grow sufficiently in numbers to cause clinical disease. Fansidar is commonly used to treat uncomplicated *falciparum* malaria^[3]. Combination drug therapy, administered concomitantly or consecutively, is common with antimalarial drugs ^[92]. Proguanil, pyrimethamine, sulphadoxine and dapsone are antimetabolites whereas tetracycline, doxycycline and minocycline are antibiotics ^[62]. Causal prophylactics (e.g. proguanil, primaquine) attack pre-erythrocytic phase; suppressive prophylactics (e.g. chloroquine, mefloquine) suppress the erythrocytic phase; suppressive cures are a form of radical cure by extended suppressive therapy (e.g. chloroquine 300mg weekly for 10 days). It may involve slow action on hypnozoites. Clinical cure involves the use of erythrocytic shizonticides (e.g. atovaquone, artemisinin, halofantrine) to terminate episode of malarial fever. But radical cure involves the use of drugs (e.g. primaquine 15mg daily for 2 weeks) to attack the hypnozoites given together with a clinical curative to achieve total eradication of the parasites ^[66, 93].

The aims of using drugs in relation to malarial infection are: to prevent and treat clinical attack of malaria; to completely eradicate the parasite from the patient's body; and to reduce the human reservoir of infection-cut down transmission to mosquito. These are achieved by attacking the parasite at its various stages of life cycle in the human host.

Antimalarial drugs exhibit considerable stage selectivity of action. A single 45 mg (0.75 mg/kg) dose of primaquine is employed immediately after clinical cure of falciparum malaria to kill the gametes and cut down transmission to mosquito ^[93].

2.8.2 CHEMICAL CLASSIFICATION OF ANTI-MALARIAL DRUGS

There are several major chemical classes of antimalarial drugs. These include 4-aminoquinoline used for treatment and chemoprophylaxis of infection with sensitive parasites (e.g. chloroquine, hydroxychloroquine, amodiaquine), quinoline methanol (e.g. quinidine, mefloquine and cinchona alkaloid (quinine) used to treat chloroquine resistant *P. falciparum*, 8 – aminoquinoline used for radical cure and terminal prophylaxis of infections with *P. vivax* and *P. ovale* (e.g. primaquine, bulaquine), biguanides (folate antagonist) for chemoprophylaxis (e.g. proguanil), tetracyclines for treatment of infections with *P. falciparum* and chemoprophylaxis (e.g. tetracycline, doxycycline), phenanthrene methanol (e.g. halofantrine) for treatment of infections with some chloroquine-resistant *P. falciparum*, amyl alcohol (lumefantrine) for treatment of *P. falciparum* in fixed combination with artemether (coartem), sesquiterpene lactone endoperoxides (artesunate, artemether, arteether) for treatment of infection with multidrug resistant *P. falciparum* and quinonefolate antagonist combination (e.g. malarone: atovaquone/proguanil) for treatment and chemoprophylaxis of *P. falciparum* infection ^[3]. Other classes; are Hydroxynaphthaquinone (atovaquone) has activity against plasmodium species, diaminopyrimidines (e.g. pyrimethamine) exhibited potent antimalarial activity. Antimalarial activity of proguanil is ascribed to cycloguanol, a cyclic triazine metabolite and selective inhibitor of the bifunctional plasmodial dihydrofolate reductase thymidylate synthetase, sulphonamides (e.g. sulphadoxine) and sulphones (e.g. dapsone) have antimalarial activity but are slow acting schizonticides that are more active against *P. falciparum* than *P. vivax*. As para-aminobenzoate analogues that competitively inhibit the dihydropteroate synthase of *P. falciparum*. The sulphonamides are used together with an inhibitor of parasite dihydrofolate reductase to enhance their antiparasmodial action. Dapsone given with the chloroquinil also has been effective for therapy of chloroquine-resistant *P. falciparum* malaria ^[64]. Acridine (e.g. mepacrine), an erythrocytic schizonticide, more toxic and less effective than chloroquine ^[60, 95].

Chloroquine and mefloquine (Long-acting quinolines) are used for chemotherapy and chemoprophylaxis of malaria, although widespread resistance is now associated with chloroquine while mefloquine treatment is associated with toxicity and resistance development. Quinine a short acting quinoline is effective in the treatment of severe and drug resistance malaria, but has a potent effect on the cardiovascular system ^[22].

Primaquine, a quinoline active against hepatic phase of some malaria parasites is contraindicated in glucose 6-phosphate dehydrogenase deficiency and pregnancy ^[96]. Atovaquone, which is given in combination with proguanil, is not effective for *P. vivax* malaria, so it is not used for children under 11 kg, pregnant women or those breast-feeding, and is contraindicated in patients with severe renal impairment ^[97]. Diaminopyrimidines used in combination with sulpha drugs (e.g. pyrimethamine-sulphadoxine) in the treatment of chloroquine resistant malaria, however, it is known that sulphonamides are potentially toxic and resistance to the antifolates is prevalent ^[98]. Sesquiterpene lactone endoperoxide derivatives such as artemisinin, dihydroartemisinin, artemether and artesunate obtained from *Artemisia annua* a Chinese plant although has been in use for more than three decades, no report of systemic human toxicity study on the plant. However, in the pre-clinical toxicity study, lesions occurred in the brain, liver, bone marrow and fetus ^[23].

2.9 IN VITRO ANTIPLASMODIAL ASSAY

The testing of new anti-malarial drugs requires that at least two steps are undertaken before testing in human may take place. In the first step, the new drug is tested in vitro and then-if promising results are obtained – it is tested in vivo ^[99].

In the first step of process, assays have been developed that focus on the drug's ability to affect parasite growth in red cells. In these assays, *P. falciparum* is the parasite used if the drug is intended for humans ^[99]. *P. falciparum* drug sensitivity assays are performed by monitoring the accumulation of the parasite protein, Histidin – Rich protein 2. (HRP 2) in the culture after lysis of the parasite cells. Quantification of HRP2 is assessed by a double-site antigen capture ELISA as described by Robin et al. ^[100]. The photometric reading obtained and the corresponding log drug concentrations are fitted to a dose response curve model using an automated curve-fitting analytical software (Table curve 2D

version 4). The results are expressed as the drug concentration resulting in 50%, 90% and 99% inhibition of parasite growth (IC_{50} , IC_{90} , IC_{99})^[101]. The development of a continuous in vitro culture system for *P. falciparum* by Trager and Jensen has provided an extremely useful system for analysis of the effects of drugs on *P. falciparum*^[91]. But several constraints limit the use of this system for drug screening (Timothy et al., 1983)^[102].

Modification of existing continuous in vitro culture methods for *P. falciparum* involves the maintenance of the parasite in RPMI/640 medium supplemented with human or rabbit serum or with the H-hypoxanthine supplemented bovine serum. The antiparasite effect of the test drug can be screened routinely against *P. falciparum* growth in bovine serum supplemented with H-hypoxanthine. Drug effect may be rapidly and accurately determined by monitoring the incorporation of H-hypoxanthine into parasite nucleic acids^[102].

Another modification of in vitro assay is green fluorescent protein (GFP) system in which the *P. falciparum* protein binds to GFP, which produces a fluorescence that can normally be detected by a microplate reader. However, fluorescence activated cell sorter (FACS) has been used to assess the parasite growth. Also, GFP-fluorescence needs to be performed in live parasites, besides the fact that ring-form stages of the parasite containing GFP are difficult to distinguish from unaffected cells, which are estimates. Therefore, to be able to quantify parasite growth, luciferase protein can be used in place of microplate reader. Luciferase reporter protein system is used. The luciferase protein is also the result of light-emitting reaction. To build a DNA construct, the Luciferase gene is strategically engineered next to a specific DNA sequence known as a promoter, which is a gene-specific sequence that triggers transcription. The luciferase system is used to investigate whether a promoter of interest is working. The working promoter transcribes the luciferase gene that results in the production of the luciferase protein which then emits light that can be quantified using a microplater. But to estimate parasite growth, cell lines are built that are infected with DNA constructs carrying the luciferase system. In each of the cell lines a specific promoter is added to the luciferase system, either the *ama-1* promoter that is schizont-specific and therefore to be active only in schizont-stage parasites, or the *eef1 aa*, which is a constitutive promoter that is expected to be working all times. The first system (*ama-1* promoter) is an in vitro assay used to evaluate a drug effect on schizont growth,

whereas a second system (*eef 1 aa*) is an in vivo test evaluated through analyzing drug effects on parasite growth during all stages^[99].

2.10 IN VIVO ANTIPLASMODIAL ASSAY

In the second step of the process, animal models, usually rodents (mice, young rats) are used to test the drug efficacy. In this step, species-specific parasites such as *P. berghei* are used according to a 4-day suppressive test. The experimental groups are treated with antiplasmodial agent at 0, 24, 48, and 72h post-infection of the animal models with *P. berghei*. Tail blood is usually taken to determine parasitaemia and haematological parameters are monitored daily during the first 7 days and thereafter every 2 days interval for a period of 2 weeks^[101]. Percentage parasitaemia, packed cell volume, hemoglobin, red blood cells count, white blood cells count and differential leucocyte count are monitored during the period. Rodent malaria parasites have been proven to be analogous to the malaria parasites of man and other primates in most essential aspects of structure, physiology and life cycle^[103].

2.11 ANTI-MALARIAL RESISTANCE

The rapid spread of resistance to antimalarial drugs present a potentially devastating threat to effective safe treatment with effective and affordable options quickly running out. The discovery of new antimalarial drugs is not keeping pace. For decades chloroquine was the main drug of choice for treatment, however increasing resistance forced its replacement in parts of Asia and South America during the 1980s and in the African countries in the 1990s^[13]. In Eastern Nigeria 40-60% of malarial cases have been reported not to respond to treatment with the drug. There is evidence that chloroquine-resistant *Plasmodium falciparum* accumulates significantly less chloroquine than susceptible parasites by an accelerated drug efflux^[104 - 106]. Various drugs, including calcium channel blockers (e.g verapamil) and tricyclic compound (e.g desipramine) have been shown to reverse or modify chloroquine resistance *in vitro*^[102 - 104]. The persistence of malaria as a public health problem is partly as a result of resistance of malarial parasites to antimalarial drugs and to insecticides by *Anopheles* mosquitoes. Unfortunately, progress in the field of vaccine production has been slow although, a breakthrough by Patarroyo *et al.* has raised some

hopes, however its usefulness to malaria endemic third world countries is yet to be determined^[15].

2.12 DEVELOPMENT OF MALARIA VACCINES

Attempts are now being made to improve the immunogenicity of antiparasite vaccines by taking into account, the requirement for T-cell as well as B-cell stimulation. Hitherto vaccines have been designed with blocking antibody in mind, but it has recently been shown that cytotoxic T cells can also be effective against the liver stage. However, the T cells of many patients living in endemic areas respond poorly or not at all to sporozoite antigens, presumably because parasites have selected antigenic variants that lead to their own survival^[71].

Vaccine produced against *Plasmodium falciparum* injected intramuscularly into 40 volunteers produced antibody response only in 9 persons. The challenge of the 9 persons by mosquito bites indicated that only 2 were protected. Unfortunately, since a single surviving sporozoite can initiate clinical malaria, protection against this stage has to be “all or nothing”^[105].

In another trial, a Colombian group was tested with a more complex antigen made by hybridization and then polymerising three separate peptides from the asexual blood parasites, which is the stage associated with the symptoms and lesions of malaria. Three of 9 volunteers, when challenged with parasites intravenously, had only transient low-level parasitaemias while the others required chemotherapy when their parasitaemia reached the previously agreed level of 0.5%^[15]. The experiment highlights the ethical difficulties of testing this type of vaccine. A much larger trial of this strategy is now in progress with the precise role of T-cell stimulation under close scrutiny and there is no universal agreement about the sort of immunity that should be aimed for^[105]. One worrying aspect is that many of the most promising parasite surface antigens are extremely polymorphic, so that a vaccine might have to contain antigens from numerous strains (as with the pneumococcal polysaccharide vaccine). It is interesting to note that, as with many parasites, some of the protective antigens are functional enzymes, whose amino acid sequences may be expected to be less variable. An advantage of the blood stage is that protection does not have to be 100% effective to benefit the patient. Moreover there are a very large number of antigens to choose from, by no means all of which have been explored^[106].

Two other approaches, not yet tried in human populations, should also be mentioned. The first is the “transmission-blocking” vaccine, aimed at preventing the development of the sexual stage of the parasite in the mosquito. Vaccines consisting of gamete- derived antigens are surprisingly effective in animal models though there are many problems to overcome, one being the hint that suboptimal levels of immunity may actually enhance the production of infective sporozoite in the mosquito. This type of vaccine can only be evaluated at the population level, and both uptake and effectiveness would probably need to be high for any impact on the level of transmission^[107].

The principal idea is to vaccinate against the disease rather than the parasite, rather in the same way as one does against tetanus and diphtheria, where it is the toxin and not the bacterium that causes the damage^[106]. No direct toxin has been isolated from the malaria parasite, but there is growing evidence for indirect toxicity via the overinduction of cytokines, particularly tumour necrosis factor (TNF), which has been implicated in the pathological changes in the brain, lung, liver, and other organs in severe malaria. If the molecules that induce TNF production can be identified, antibodies against them might form the basis of an “anti-disease” vaccine^[106]. In summary, it seems certain that several more field trials will be necessary to evaluate the various strategies now under consideration, and it may be that in the end some kind of “cocktail” of the strongest antigens of each kind will give the best all-round results^[105].

3.0 CONCLUSION

Because of the long recognition of malaria through anthropology, a lot was known about control and treatment of malaria. But developing of vaccines is not keeping pace due to antigenic shift of all the stages of Plasmodium, in vitro and vivo antiparasitic assays need to be improved upon with a view to proffering solution to episode of malaria resistance. In the local areas where malaria is sporadic and endemic, there is need to combine chemotherapy with ethnomedicine since many malaria patients from developing countries cannot afford costlier effective and less toxic antimalarials.

733 REFERENCES:

- 734 1. Ukoli FMA: *Introduction of Parasitology in Tropical Africa*, Chichester: John Wiley and
735 Sons Ltd.; 1984: 404.
- 736 2. Ukoli FMA: **The biology and natural history of malaria. Proceedings of the fifth**
737 **annual convention and scientific assembly.** *Arch Ibad Med* 2003, **1**(2): 35-36.
- 738 3. Katzung B: *Basic and Clinical Pharmacology*. International edition. London: McGraw
739 Hill London; 2004: 864 – 873.
- 740 4. Bruce-Chwat LJ: *Essential Malariology*. London: William Heinemann Medical Books
741 Ltd.; 1980: 354.
- 742 5. Brabin BJ: **Malaria in pregnancy. Its importance and control.** *Postgrad Doc. Afr*
743 *1989*,**2**: 57-59.
- 744 6. Abdu-Aguye I: **Medicinal herbal research in West Africa.** In proceedings of the
745 24th *Annual Regional Conference of the West Africa Society for Pharmacology (WASP)*:
746 22 - 25 October, 1997, Usmanu Danfodiyo University, Sokoto; 1997: 2-3.
- 747 7. WHO: **Promotion and development of training and research in traditional**
748 **medicine.** *Technl Report* Geneva; 1997: 622.
- 749 8. Rabo ET, Sanusi SS: *An Inventory of Medicinal Plants of the Nigerian Savannah*,
750 Lagos: Levithan Books; 2001: 21-24.
- 751 9. Wambebe C: **Development and production of standardized phytomedicines.** *West*
752 *Afr J Pharm.* 1998, **12**(2): 13-24.
- 753 10. WHO: **The promotion and development of traditional medicine.** *Techn Research Ser*
754 Geneva 1992: 143.
- 755 11. Ghirotti M: **The possible role of ethnoveterinary medicine in the delivery of more**
756 **effective animal health services in tropical and sub- tropical areas.***Giornate Halianio*
757 *Dimedicine Tropicale* 1996, **1**: 34 -39.
- 758 12. WHO: **World malariareport.** WHO Bull. 2008: 99.
- 759 13. WHO: Rolling back malaria. *The World Health Report*, 1999: 49.
- 760 14. The Health Exchange: Roll Back Malaria Facing The Challenge in Complex
761 Emergencies. 2001: pp 62.

- 762 15. Pattaroyo ME, Amador R, Clarjo P, Moreno A, Guzman F, Romero P: **A synthetic**
763 **vaccine protects human against challenging with asexual blood stage of**
764 **plasmodium falciparum malaria.** Nature 1988, **332**: 158 – 161.
- 765 16. Iwu MM: *Handbook of African Medicinal Plants*. London; CRC Press, Boca Raton,
766 1993: 12-14.
- 767 17. Saganuwan SA, Yatswako S: **Malaria parasites of clinical and laboratory importance**
768 **– an update.** J Med Pharmaceut Sci 2006, **2**(3): 96 – 105.
- 769 18. Hackskaylo MM: **Culinary garden.** In *The National Herb Garden*. Edited by Ober R.
770 Springfield; The Herb Society of America; 1996: 79 – 93.
- 771 19. Davidson A: *The Oxford Companion to Food*. Oxford:Oxford University Press; 1999.
- 772 20. Remilard RL, Wynn SG: Herbal medicines In *Textbook of Veterinary Internal*
773 *Medicine: Diseases of the Dog and Cat*. 6th edition. Edited by Ettinger, SJ, Feldman FC.
774 Philadelphia: Elsevier; 2005: 524-526.
- 775 21. Hoareau L, Edgar JD: **Medicinal plants: A re-emerging health aid.***Electr J Biotechnol*
776 1999, **2**(2): 56 – 70.
- 777 22. Bateman DN, Dyson EH: **Quinine toxicity: adverse drug reaction.** *Acute poison Rev.*
778 1986, **5**: 215- 233.
- 779 23. Johann-Liang R, Albracht R: **Safety evaluations of drugs containing artemisinin**
780 **derivatives for treatment of malaria.** *Clin Infect Dis* 2003, **36**: 1626 -1627.
- 781 24. Tella A: **The effects of Azadirachta indica in acute Plasmodium berghei malaria.** *Nig*
782 *Med J* 1965. **7** (3); 258 –263.
- 783 25. Mann A, Gbate M, Nda Umar A: *Medicinal and Economic Plants of Nupeland*, Bida:
784 Jube Evans Books and Publications; 2003: 275.
- 785 26. Luize PS, Tiunan TS, Morello LG, Maza PK, Ueda-Na Kamura T, Filho BPD, Cortez
786 DAG, de Mello CP, Nakamura CV: **Effects of medicinal plant extracts on growth of**
787 **Leishmania (L.) amazonensis and Trypanosoma cruzi.** Braz J Pharmaceut Sci 2005,
788 **14**(1): 85 – 94.
- 789 27. de Mesquita ML, Grellier P, Mambu L, de Paula JE, Espindula LS: **In vitro**
790 **antiplasmodial activity of Brazilian Cerrado plants used as traditional remedies.** J.
791 Ethnopharmacol 2007, **110**(1): 165 – 170.
- 792 28. Devkota A, Jha PK: **Biology and medicinal characteristics of Centella asiatica.** In: Jha,
793 **P.K., Karmacharya, S.B., Chettri, M.K., Thapa, C.B. and Shrestha, B.B.**

- 794 **(eds)** Medicinal plants in Nepal: An Anthology of Contemporary Research Ecological
795 Society (ECOS), Kathmandu. Edited by Karmachary SB, Chettri MK; Thapa CB,
796 Shrestha BB. 2008.
- 797 29. Laouer H, Hireche-Adjai Y, Prado S, Boulaacheb N, Akkal S, Singh G, Singh P, Laidorov
798 VA, Szizeparniak L: **Chemical composition and antimicrobial activity of essential oil**
799 **of Bupleurum montanum and Bupleurum Plantagineum**. Nat Prod Commun 2009,
800 4(11): 1605-1610.
- 801 30. Esmaeili S, Naghibi F, Mosaddegh M, Sahramaward S, Ghafari S, Abdullah NR:
802 **Screening of antiplasmodial properties among some traditionally used human**
803 **plants**. J Ethnopharmacol 2009, **121** (3): 400-404.
- 804 31. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Ray C: **Screening of Indian plants for**
805 **biological activity**. Ind J Exper Biol 1968, **6**(4): 232 – 247.
- 806 32. Okokon JE, Ubulom PM, Udokpoh AE: **Antiplasmodial activity of Setaria megaphylla**.
807 Phytother Res 2007, **21**(4): 366 – 368.
- 808 33. Waaka PJ, Gumede B, Smith P, Folb PI: **The in vitro and in vivo antimalarial activity**
809 **of Cardiospermum halicacabum L. and Momordica foetida Schundi Et Thonn**. J
810 Ethnopharmacol 2005, **99**(1): 137 – 143.
- 811 34. Amorim CZ, Marques AD, Cordeiro RS: **Screening of the antimalarial activity of**
812 **plants of the Cucurbitaceae family**. Mem Inst Oswaldo Cruz 1991, **86**(2): 177 – 180.
- 813 35. Mustofa, Sholikhah EN, Wahyrono S: **In vitro and in vivo antiplasmodial activity and**
814 **cytotoxicity of extract of phyllanthus niruri L. herbs traditionally used to treat**
815 **malaria in Indonesia**. Southeast AS J Trop Med Public Health 2007, **38**(4): 609 – 615.
- 816 36. Coker HAB, Adesegun SA: **The malaria scourges the place of complementary**
817 **traditional medicine**. *Nig Med Pract* 2006, **49**(5): 126-132.
- 818 37. Gupta SS: **Prospects and perspective of natural products in medicine**. *Ind J*
819 *Pharmacol* 1994, **26**:1-12.
- 820 38. Saganuwan SA: **Some tropical plants with antihypertensive, antiasthmatic and**
821 **antidiabetic value**. *J Herb Spice Med Plant* 2009, **15**(1):24-44.
- 822 39. Geidam YA: **Antibacterial and toxicological studies of aqueous leaf extract of**
823 **Psidium guajava (guava) in Chickens**. *Ph.D. Thesis*, University of Maiduguri,
824 Maiduguri, Nigeria.
- 825 40. Saganuwan SA, Gulumbe ML: **Evaluation of in-vitro antimicrobial activities and**
826 **phytochemical constituents of Cassia occidentalis**. ARI 2006, **3**(3):566 – 569.

- 827 41. Saganuwan SA: **Toxicological and antimalarial effects of aqueous leaf extract of**
828 **Abrus precatorius (Jecquirity bean) in Swiss albino mice.** Ph.D. Pharmacology
829 Thesis, Sokoto: Usmanu Danfodiyo University, 2012: 242.
- 830 42. Tracy JW, Webster: Drugs used in the chemotherapy of protozoal infections. In
831 *Goodman and Gilman's The pharmacological Basis of Therapeutics*. Edited by
832 Hardman JG, Limbird LE, Mohinstt PB, Ruddon RW, Gilman AG. Ninth edition.
833 McGraw Hill Companies; 1996: 1905.
- 834 43. Smyth JD: *Animal Parasitology*. Cambridge low price edition. Cambridge: University
835 of Cambridge Press, 1996: 126-136.
- 836 44. Bradley DJ: **The last and the next hundred years malariology.** *Parasitologia* 1999,
837 **41:11-18.**
- 838 45. Laveran A: Pludism. In *Trans*. Edited by Martins JW. London: *The New Sydenham*
839 *Society*; 1983: 197.
- 840 46. MacCallum WG: **On the flagellated form of the malaria parasite.** *Lancet* 1897,
841 **2:1240-1241.**
- 842 47. MacCallum WG: **On some peculiar pigmented cells found in two mosquitoes fed on**
843 **malaria blood.***Br Med J* 1987, **2:1786-1788.**
- 844 48. Ross R: **On the haematozoan infections of birds.** *J Exp Med* 1897, **3: 117-136.**
- 845 49. Ross R: Researches on malaria. *JR Army Med Corps* 1905, **4: 474.**
- 846 50. Kettle DS: *Medical and Veterinary Entomology*, Wallingford: CAB International 1993:
847 513-541.
- 848 51. WHO: **Malaria actions: programme, severe and complicated malaria.** *Tran Royal Soc*
849 *Med Hyg* 1986, **80: 1-50.**
- 850 52. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell
851 Da, Bannister BA: **UK malaria treatment guidelines.** *J. Infect* 2006, **54: 111 – 121.**
- 852 53. WHO: **Roll back malaria: a global partnership.** *WHO* Geneva; 1995.
- 853 54. Cheesebrough M: *District Laboratory Practice in Tropical countries* Part 1. Low price
854 edition. Cambridge University Press; 2005: 434.
- 855 55. Disease Watch: **Malaria. TDR Nature Reviews Microbiology** In *District laboratory*
856 *practice in Tropical Countries*. Edited by Cheesebrough M. Cambridge: Cambridge
857 University press; 2004: 454.

- 858 56. Dellacollete C: **Malaria epidemic response: What the clinician needs to know.***Mera*,
859 2004: 3.
- 860 57. Ukoli FMA: Prevention and Control of Parasitic Diseases in Tropical Africa: The Main
861 Issues, Ibadan: University Press Plc 1992: 192.
- 862 58. Supargiyano S, Bretscher MT, Wijayanti MA, Sutanto I, Nugraheni D, Rozqie R,
863 Kosasih AA, Sulistiywati S, Hawley WA, Lobo NF, Cook J, Drakeley CJ: Seasonal
864 changes in the antibody responses against plasmodium falciparum merozoite surface
865 antigens in areas of differing malaria endemicity in Indonesia. *Malaria Journal* 2013;
866 12: 444.
- 867 59. Gilles HM: **Diagnostic methods in malaria.** In *Bruce-Chawtt Essential Malariology*.
868 Third edition. Edited by Gilles HM, Warrell DA, Great Britain: Division of Holder
869 Stoughton; 1993: 78-95.
- 870 60. Akubue PI: **Malaria.** In *Textbook of Pharmacology*. Edited by Akubue PI. Onitsha:
871 Africana first publishers limited; 2006: 536.
- 872 61. Bennett PN, Brown MJ: Protozoal infection. *Clinical Pharmacology* Edited by Bennet
873 PN, Brown MJ. New Delhi: Churchill Livingstone; 2005: 789.
- 874 62. Nester EW, Anderson DG, Roberts Jr, CE, Pearsall NN, Nester MT, Hurley D:
875 *Microbiology: A Human Perspective*. Fourth edition, New York; McGraw Hill; 2004:
876 731-738.
- 877 63. Shapiro TA, Goldberg DE: Chemotherapy of protozoal infections (Malaria). In:
878 *Goodman and Gilman's, The pharmacological Basis of Therapeutics*. Edited by
879 Brunton LL, Lazo JS, Parker KL, New York: McGraw Hill Medical Publishing; 2006:
880 1021 – 1045.
- 881 64. Rang HP, Dale MM, Ritter JM, Flower RJ: Rang and Dale's Pharmacology. 6th edition.
882 Philadelphia: Churchill Livingstone, 2008: 829.
- 883 65. Sibley L, Sipe TA, Koblinsky M: **Does traditional birth attendant training improve**
884 **referral of women with obstetric complications: a review of the evidence.** *Soc Sci*
885 *Med* 2004, **59**(8): 1757-1768.
- 886 66. Brooks GF, Butel JS, Nurse SA: *Jawetz, Melnick & Adelberg's Medical Microbiology*.
887 International 23rd edition. London: McGraw Hill; 2004: 677-683.
- 888 67. Barbara JAJ: *Microbiology in Blood Transfusion*, London: Wright. PSG; 1983: 97-103.

- 889 68. Craig A, Scherf A: **Molecules on the surface of the Plasmodium falciparum infected**
890 **erythrocytes and their role in malaria pathogenesis and immune evasion.** Molecul
891 Biochem Parasitol 2001, **115**: 129-143.
- 892 69. Stanier RY, Ingraham JL, Wheelis ML, Painter PR: *The Microbial World*. Fifth edition.
893 New Jersey: prentice-hall, Englewood Cliffs; 1986: 647 - 656.
- 894 70. Conrald ME: **Diseases transmissible by blood transfusion: Viral hepatitis and other**
895 **infectious diseases.** *Semin Haematol* 1981, **18**:122-146.
- 896 71. Hardman JG, Limbird LL, Molinoff PB, Ruddon RW, Gilman AG: Goodman and
897 Gilmen's. ***The Pharmacological Basis of Therapeutics* 9th edition.** London: McGraw
898 Hill; 1996: 1905.
- 899 72. Viser BJ, Wieten RW, Nagel IM, Grobusch MP. **Serum lipids and lipoproteins in**
900 **malaria-a systematic review and meta-analysis.** *Malaria Journal* 2013; 12: 442.
- 901 73. Lau TY, Sylri M, William, T: Mutational analysis of Plasmodium falciparum
902 dihydrofolate reductase and dihydropteroate synthase in the interior division of
903 Sabah, Malaysia. *Malaria Journal* 2013; 12: 445.
- 904 74. Philips RS: **Current status of malaria and potential.** *Clin Microbiol Rev* 2001, **14**(1):
905 208-226.
- 906 75. Witworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, Omoding N, Okongo
907 M, Malamba S, Ojiwiya A: **Effect of HIV and increasing immunosuppression on**
908 **malaria parasitaemia and clinical episodes in rural Uganda adults: a cohort study.**
909 *Lancet* 2000, **356**:1051-1056.
- 910 76. Francesconi, Fabiani M, Dente DG, Lukwiya M, Okwey R, Ouna J, Ochakahom R, Cian
911 F, Decnich S: **HIV, malaria parasites and acute febrile episodes in Ugandan adults: a**
912 **case control study.** *AIDS* 2001, **15**:2445-2450.
- 913 77. Bastos F, Barcellos C, Lowndes C, Friedman S: **Co-infection with malaria and HIV in**
914 **injecting drug user in Brazil: a new challenge to public health.***Addict.* 2004, **94**(8):
915 1165-1174.
- 916 78. Jeffery GM: **Infectivity to mosquitoes of Plasmodium vivax and plasmodium**
917 **falciparum under various conditions.***Amer J Trop Med Hyg* 1960: **9**: 315-320.
- 918 79. Bray RS: **Observations on the cytology and morphology of the mammalian malaria**
919 **parasites. A process of apparent plasmotomy in the preerythrocytic phase of**
920 **Laveranian falciparum.***Riv Parasit.* 1960, **21**: 267-276.

- 921 80. Horsefall WR: *Medical Entomology: Arthropods and Human Diseases*; New York: The
922 Ronald press Company; 1962: 338-347.
- 923 81. White NJ: In *Manson's Tropical Diseases* Edited by Cook G. London: WB Saunders;
924 1996: 1087-1164.
- 925 82. WHO: *Quality Control Method for Medicinal Plants Materials*, Switzerland; 1998:
926 115.
- 927 83. Adeoti OM, Anumudu CI, Adejumbi CA, Siyanbola MF: **Presumed malaria and**
928 **human immunodeficiency disease: a challenge to health planners.***J. Med.*
929 *Pharmaceut. Sci.***3**(3): 75-80.
- 930 84. Klayman DL: **Qhinghaosu (artemisinin): an antimalarial drug from China.***Sci* 1985,
931 **228**:1049-1055.
- 932 85. Namdeo AG, Mahadik K, Kadam SS: **Antimalarial drug – *Artemisia annua*.**
933 *Pharmacogn Magaz* 2006, **2**(6): 106-111.
- 934 86. Jimmy ED, Usuh IF, Etim OE, Nwidi LL: **Haematologic responses in comparative**
935 **doses of chloroquine, fansidar, lapdap, amalar and cotexicin.** *J Med Pharmaceutic*
936 *Sci* 2006, **2**(4): 1-4.
- 937 87. Terkuile FO, Praise ME, Verhoeff FH, Udhayakuma V, Newman RD, Vanejik A,
938 Rogerson, Steketee RW: **The burden of co-infection with human immunodeficiency**
939 **virus type 1 and malaria in pregnant women in sub-Saharan Africa.***Am J Trop Med*
940 *Hyg* 2004, **71**: 41-54.
- 941 88. Rosenthal PJ: *Basic and Clinical Pharmacology*. Ninth edition, New Delhi: MC Graw
942 Hill; 2004: 1202.
- 943 89. Tragar W, Jensen JH: **Human malaria parasites in continuous culture.** *Sci* 1976, **193**:
944 673-675.
- 945 90. Greenstein B, Gould D: Trounce's Clinical Pharmacology for Nurses, 18th edition.
946 Edinburgh: Churchill Livingstone; 2009: 483.
- 947 91. Abrams AC: Clinical Drug Therapy, 7th edition, Philadelphia: Lippincott Williams and
948 Wilkins, A. Wolters Klower Company; 2004: 1032.
- 949 92. Tripathi KD: *Essentials of Medical Pharmacology*. 5th edition: New Delhi: Jaypee
950 Brothers Medical Publishers (p) Ltd.; 2003: 735-748.
- 951 93. Carson PE, Flanagan CL, Ickes CE, Alving AS: **Enzymatic deficiency in primaquine**
952 **sensitive erythrocytes.** *Sci.* 1956,**124**: 484 -485.

- 953 94. White N: **Antimalarial drug resistance and combination chemotherapy.** *Philos Trans*
954 *R Soc* 1997: 354: 739-749.
- 955 95. Bjorkman A, Phillips-Howard PA: **Adverse reactions to sulfa drugs: implications for**
956 **malaria chemotherapy.** *Bull WHO* 1991, **69**:297-304.
- 957 96. Franke-Fayard B, Djokovic D, Dooren MW, Rameser J, Waters AP, Falade MO,
958 Kranendonk M, Martinelli A, Cravo P, Janse CJ: **Simple and Sensitive antimalarial**
959 **drug screening in vitro and in vivo using transgenic luciferase expressing**
960 **plasmodium berghei parasites.** *Int J Parasitol* 2008, **20**: 1 – 5.
- 961 97. Bahamontes – Rosa N, Bucher K, Held J, Robin A, Hoffmann WH, Flitsch SL, Kremsner
962 PG, Kun JFJ: **In vivo anti-malarial effect of β -amino alcohol 1t on Plasmodium**
963 **berghei.** *Parasitol Res* 2009, **10**: 1-9.
- 964 98. Timothy GG, Divo AA, Jensen JB: **An in vitro assay system for the identification of**
965 **potential antimalarial drugs.** *J Parasitol* 1983, **69** (3): 577-583.
- 966 99. Carter R, Diggs CL: **Plasmodium of rodents.** In *Parasitic Protozoa Volume III.* Edited
967 by Kreier JP. New York: Academic press; 1977: 359-465.
- 968 100. Krogstad DJ: **Efflux of chloroquine from plasmodium falciparum: Mechanism of**
969 **chloroquine resistance.** *Sci* 1987, **238**: 1283-1285.
- 970 101. Crownman AF, Karecz: **Drug resistance and the P-glycoprotein in homologues of**
971 **plasmodium falciparum:***Semin cellbiol* 1993, **4**: 29-35.
- 972 102. Olliaro PL, Trigg PI: **Status of antimalaria drugs under development.***Bull WHO* 1995,
973 **73**(5): 565-571.
- 974 103. Bitonti AJ: **Reversal of chloroquine resistance in malaria parasite *plasmodium***
975 ***falciparum* by desipramine.***Sci.* 1988, **242**:1301-1303.
- 976 104. Martins SK, Oduola AMJ, Mkilhous WK: **Reversal of chloroquine resistance in**
977 ***plasmodium falciparum* by verapamil.** *Sci* 1987, **242**:1301-1303.
- 978 105. Playfair JHL, Blackwell JM, Miller HRP: Parasitic diseases. In *Modern Vaccines, Current*
979 *Practices and New Approaches.* Edited by Moxon ER, Great Britain: Edward Armed;
980 1990: 150.
- 981 106. Playfair JHL, Taverne J, Bate CAW, De Souza JB: **The malaria vaccine: anti-parasite or**
982 **anti-disease?***Immunol Today* 1990, **11**: 25-27.

983 107. Mendis KN, Munesinghe YD, De Silva YNY, Keragalla I, Carter R: **Malaria**
984 **transmission-blocking immunity induced by natural infections of *Plasmodium vivax***
985 **in humans.** *Infect Immun.* 1987, **55**: 369-77.

986

Table 1: Tropical plants that are use to treat malaria in Nigeria

Plant material, family, genus, species & English names	Vernacular names	Plant part(s) used	Therapeutic regimen(s)	Pharmacologic/ toxic principle(s)
Amaranthaceae <i>Achyranthes aspera</i> (Devils horsewhip)	Hakorinmaciji (H) Aburo (Y) Egyagi (N)	Whole plant	Decoction taken once: Steam relief headache	Alkaloid, potassium salt
Amaranthaceae <i>Alternanthera sessilis</i> (Sessile joyweed)	Maikaidubu (H) Masantogi (N) Dagunro (Y)	Whole plant	Decoction taken orally	Alkaloids
Amaranthaceae <i>Pupalia lappacea</i>	Marin kusu (H) Emaagbo (I) Mamarigbo (N) Ose (Y)	Whole plant	Leaf or root decoction taken orally	-
Poaceae <i>Elevisine indica</i> (Goose grass)	Ciyawarjuji (H) Chinchere (N) Ese-Kannakanna (Y)	Whole plant	Make decoction and take once daily	Elevisine
Guttiferae <i>Garcinia kola</i> (Bitter kola)	Namijin goro (H) Akilu (I) Ewogichi (N) Orogbo (Y)	Seed, stem root	The powder is taken: It can be chewed also	Kolavirone, ametoflavine, tannins
Irvingiaceae <i>Irvingia gabonensis</i> (wild mango)	Goron biri (H) Ogbono (I) Kpeakpea (N) Eso oro (Y)	Leaves	Leaf decoction is made and taken	Protein, fat
Labiatae	-	Leaves	Cold water maceration is	-

Ocimum basilicum			taken	
Anacardaceae	Kashew (H)	Stem bark	Decoction taken once	Cardol, phenol, gallic acids,
Anacardium occidentale	Okpokpo (I)		daily	resorcinol, anacardic acid
(Cashew)	Kashiwu (N)			
	Kaju (Y)			
Anacardaceae	Mangwaro (H)	Leave, stem bark	Decoction is made with	Resins, glycoside, quercetin,
Mangifera Indica (Mango)	Mangolo (I)		other additives and taken	flavonoids
	Mungoro (N)		oftenly: boil and inhale	
	Mangoro (Y)		steam	
Anacardaceae	Dinya (H)	Stem bark	Dried stem bark	Tannins
Scleocarya birrea	Jinjere goyi (N)		decoction is taken twice	
			daily	
Anacardaceae	Tsadar masar (H)	Seed, stem, stem	Decoction or infusion is	Gerannin, galloylgerannin,
Spondias mombin	Jinkara (I)	bark, fruit	taken daily for 1-7 days	geraniin, galloylgeraniin
(Hog plum)	Jinjerechi (N)			
	Akika (Y)			
Annonaceae	Uwar banza (H)	Leaf, root	Root decoction is taken	-
Carissa edulis			once daily	
Annonaceae	Kasfiya (H)	Twigs, leaves	Decoction from twigs leaf	Crossptine, phytosterol,
Crossopteyx febrifuga	Nambi sunsun (N)		is taken orally	pholobaphene β -quinovine
	Ayeye (Y)			
Apocynaceae	Wadda (H)	Stem, leaves	Infusion is taken daily;	Rauwolfine, reserpine,
Rauwolfia vomitoria	Akata (I)		leaf powder is taken with	rescinanmine, aijimaline,
	Lyalyagi (N)		porridge	alstonine, yohimbine,
	Ira (Y)			saposterol, serpentine
Apocynaceae	Ahun (Y)	Root	Make decoction and take	-

Alstonia boonei			twice daily	
Asteraceae	Ekpe gbakun (N)	Whole plant	Make decoction with	Pinene, limonene, candinene,
Chromolaena odorata	Akintola-ta-ku (Y)		potash and take once	flavonoids
(Siam weed)			daily	
Asteraceae	-	Leaves	Juice from the leaves with	Acanthospermolides, inulim
Acanthospermum hispidus			potash once daily	
(Star bur)				
Asteraceae	Rariya kasa (H)	Whole plant	Decoction is taken once	-
Chrysanthemum indicum			daily	
Combretaceae	-	Whole plant	Cold water infusion with	-
Tridax procumbens			potash is taken	
(Tridax)				
Compositae	Tsula (N)	Stem bark, leaves	Leaf infusion or stem bark	Vernodalin, vernomygdin,
Vernonia amygdalina	Shiwaka (H)	(Root is very	decoction is taken daily	vernolepin, vernolide,
(Bitter leaf)	Ewuro (Y)	poisonous)		flavonoid
	Olubo (I)			
Compositae	-	Whole plant	Decoction is taken orally	Vernonin, amyrinacetate,
Vernonia cinerea (little				lupeol acetate, vernomoside,
iron weed)				β -amyrin, sesquiterpine, β -
				sitosterol, pene lactine,
				stigmasterol, luperol, α -
				spinasterol
Compositae	-	Whole plant	Decoction is taken orally	Vernonin
Vernonia perrottetii				
Balanitaceae	Aduwaa (H)	Bark, seed (it	Decoction of either bark	Disogenin, sapogenin,
Balanites aegyptiaca	Adua (N)	causes nephrosis	or seed is taken 1-3 days	yamogenin, flavonoids,

(Desert date)		and hepatitis)		triterpenoid, sterols, carotenoids
Bignoniaceae	Aduruku (H)	Roots, leaves	Infusion is taken daily	Alkaloids, tannins, flavonoids
Newboldia laevis (Tree of life)	Dinberechyamile (N)			
	Ogirisi (I)			
	Akoro (Y)			
Bombacaceae	Rimin (H)	Leaves, barks,	Decoction is taken oftenly	-
Ceiba pentandra	Kada (H)	roots		
	Akpu (I)			
	Kuchi (N)			
	Ogungun (Y)			
Boraginaceae	Karkashin korama (H)	Whole plant	Infusion or decoction taken daily	Indicine-N-oxide, saponins, tannins
Heliotropium indicum (Wild clary)	Etigulu (N)			
	Ogbe-akuko (Y)			
Caesalpiniaceae	Tafasar masar (H)	Leaves	Infusion is taken once	Toxalbumin, anthracene
Cassia occidentalis (Negro coffee)	Rere (Y)	(Toxalbumin is destroyed by roasting)	daily	glycoside, sennoides, flavonoids
	Gaya (N)			
	Akede ogbara (I)			
Caesalpiniaceae	Ilegbere (Y)	Whole plant	Decoction taken daily	-
Chamacrosta rotundifolia	Damma (N)			
Caesalpiniaceae	Maje (H)	Stem bark, leaves,	Decoction taken daily;	Alkaloids, tannins, gum
Daniellia oliveri (Ilorin balsam)	Ozabwa (I)	bark, leaf buds	powder can also be taken	
	Danoli (N)			
	Iya (Y)			
Caesalpiniaceae	Kalgo (H)	Fresh leaves, dried	The decoction of the first	Alkaloid, tannin
Piliostigma thonningii	Okpoatu (I)	stem bark, root	3 is taken; fruit powder	

(Thoning's piliostigma)	Bafin (N) Abafe (Y)	bark, fruits	infusion is taken daily	
Caesalpiniaceae Tamarindus indica	Tsamiya (H) Darachi (N) Ajagbon (Y) Icheku-oyibo (I)	Leaves, fruits, fresh stem bark	Decoction made with potash or cold water infusion is taken daily	Tartaric acid, citric acid, malic acid, tannins
Capparidaceae Cleome viscosa (Chicken weed)	Egyagi (N) Epira (Y)	Whole plant	Decoction is taken orally	-
Caricaceae Carica papaya (Pawpaw)	Gwanda (H) Konkenii (N) Ojo (I) Ibepe (Y)	Seed, root	Cold water infusion or decoction is made. Half a cup is taken daily	Papain, cryptoxanthin, glycosides polyphenols
Celastraceae Maytenus senegalensis	Namiji tsada (H) Kuku kama (N) Shepolohun (Y)	Roots, leaves	Decoction or infusion is made and taken daily	Maystansine, flavonol
Combretaceae Pteleopsis habeensis	Lallen giwa (H) Shinci (N)	Leaves	Decoction with Xylopia aethiopica and Capsicum frutescens taken orally	-
Canelliaceae Warburgia ugandensis (Fever tree)	-	Dried stem bark, roots, leaves	Decoction or infusion is taken daily	Drimenol, warbugin, warburgiadine, ugandesoline, muzigachial
Solanaceae Withania somnifera	Karama anta (H)	Leaves	Powdered leaf is taken; enema of decorticated root is used on infants	Withanine, withernolide, witherferin
Combretaceae	Kimbar maharba (H)	Roots, stem,	Cold water infusion of the	Alkaloid

Brysoncapus coccineus	Oka (I) Darabagi (N) Ade (Y)	leaves	root and that of lawsonia inermis; take a tumbler daily in the morning	
Ebanaceae	Faru (H)	Root bark, stem	Decoction is taken once	Phembagin, scopolin, tannin
Dicrypyros mespiliformis (West African Ebony)	Musunchi (N) Igududu (Y)	bark, leaves, roots, (abortifacient)	daily	
Euphorbiaceae	-	Leaves, stem bark, root	It is used to prepare malaria mixture with other leaves; taken once	Inulin, alchornin, tannin, alkaloid
Alchornea cordifolia (Christmas bush)				
Euphorbiaceae	Binida zugu (H)	Fruits, leaves,	Decoction is taken half	Curcin, inulin, tetramethyl-
Jatropha curcas (Fignut)	Olulu-idu (I) Kasha'a (N) Botuje (Y)	root, seeds	tumbler daily	pyrazine, phobolesters
Euphorbiaceae	Rogo (N)	Leaves	Decoction is taken once	Hydrocyanide, tannins,
Manihot esculentus (Cassava)	Rogo (H)		daily	alkaloid, saponins
Euphorbiaceae	Alambu (H)	Whole plant	Decoction is taken once	Tannins, saponins, inulin
Phyllanthus amarus (Egg noma)	Sunyegboro – sunzuma (N) Debi-sawo (Y)		daily	
Fabaceae	Fakuwari (H)	Roots, stem bark	Decoction is taken once	Alkaloids, vanillic acid,
Xanthoxylum	Ata (Y)		daily	xanthoxyloid, 2-hydroxy
xanthoxyloides (African satin wood)	Kosonkori (N)			benzoic acid
Graminae	Eto lemu (N)	Leaves	Tea is prepared and taken	Limonine, neryl, geraniol,
Cympogon citratus (Iemon)	Waape (Y)		oftenly	citronellal, campene,

grass)					triterpenes, flavonoids
Lamiaceae	Daidoy atagida (H)	Leaves	Decoction taken thrice		Eugenol, thymol, camphor
Ocimum gratissimum (Basil fever plant)	Nehonwu (I) Tanmotswagi-wawagi (N) Esinri (Y)		daily		carryophylline
Liliaceae	Lubasa (N)	Bulb	The leaves are chewed for 10 days		Riboflavin, alliin, sulphur , allicin compounds
Allium cepa (Onion)	Alubasa (H)				
Liliaceae	Tafarnuwa (H)	Rhizomes	Decoction of fresh or dry leaves is taken for 10 days		Allicin, alliin, alliinase, flavonoides, cyanogenic glycoside
Allium sativum (Garlic)					
Loganiaceae	Kookiyar (H)	Leaves, fruits (It is poisonous)	Infusion is taken once daily		Nigitanin, barterine, kagerine, kribine, strychnine, lirioresinol
Strychnos spinosa (Nux-vomica)	Manvovogi (N) Alako (Y)				
Leguminosae	-	Bark	Decoction is taken twice daily		-
Entalida plaseoloides					
Malvaceae	Kpami (N)	Fresh fruits, leaves	-		Fernesol
Abelmonchus esculentus (Lady's finger)	Kubewa (H)				
Malvaceae	Sangii ekoti (N)	Whole herb	Decoction is taken orally		Alkaloid, flavonoid, prostaglandin, tannins
Sida acuta					
Ceratonia siliqua (Carob bean)	-	Seeds	Molasses are extracted from seeds and taken accordingly		Molasses gum
Meliaceae	Dogon yaro (H)	Stem bark, root	Decoction of stem bark or		Nimbin, nimbidion, nimbidin,

Azadirachta indica (Neem tree)			root is taken orally	salanin, meliacin
Meliaceae Khaya senegalensis (Mahogany)	Madaaci (H)	Stem bark, leaves	Decoction is taken twice daily	Scopoletin, sterol, limonoid gedunin
Meliaceae Trichila emetic	-	Stem bark, root, leaves	Decoction is taken once daily	-
Mimosasae Dichrostachys cinerrea (Cow thorn)	-	Roots, fruits, leaves	A tumbler of hot decoction is taken daily	Tannins, alkaloids
Mimosasae Parkia biglobosa (Niffa)	Dorowa (H)	Leaves, stem bark, fruits	Make decoction and take once daily	Alkaloid, saponin, tannin
Moraceae Ficus thonnigii	-	Leaves, fruits	Decoction is taken once daily	-
Moraceae Musanga cercropioides (Umbrella tree)	-	Leaves, roots, stem	Decoction is taken orally	-
Myristicaceae Psidium guajava (Guava)	Gwaba (H)	Leaves	Decoction is taken daily	Quarcetin, flavonoids, sapogenins, eugenol
Ochinaceae Lochira lanceolata (Iron wood)	Namijin Kade (H), Okopia (L), Maganchi (N), Iponhon (T)	Stem, bark, root	The powder is taken with meat when required	Alkaloid, tannin, saponin, resin
Onagraceae Ludwigia octovalris	Shashatau (H)	Whole plant	Leaf decoction is taken once daily	-

(Willow)

Palmae	Kwakwa (H) Akibeka (I)	Bark, root, nut,	Decoction or infusion of	Saponin, tannin, glycerides
Cocos nucifera (Coconut palm)	Yikunu Kputa (N) Agbon (Y)	leaves, fruit	bark, rook, leaves is taken once daily	
Palmae	Dabbino (H) Dobino (N)	Dried fruits	The fruits are eaten	-
Phoenix dactylifera	Okun (Y)			
Papilionaceae	Idon zakara (H) Ojologbo	Leaves	Cold water maceration or	Abrin, abrine, abricin,
Abrus precatorius (Jecquirity bean)	(Y) Eyekosun dargii (N)		dried powder is taken for	abricane
Papilionaceae Pterocarpus erinaceus (African rosewood)	Otoberebere (I) Madobiya (H) Aze eju (I) Zanchi (N) Apepe (Y)	Stem bark, leaves, fruits	Decoction or infusion taken 1-3 times daily	Alkaloid, tannins, resins
Papilionaceae	Samaci (H) Sabanigi (N)	Whole plant	Decoction is taken once	Tephrosin
Tephrosia bracteolate	Riro (Y)		daily	
Piperaceae	Masoro (H) Azeegu (I)	Fruits, leaves	They are used as	Charicine, piperine,
Piper guinense (West African black pepper)	Masoro (N) Iyere (Y)		adjuvants and taken per os	guinesine, wisanine, dihydrowisanine
Rosaceae	Gwaza (H) Putu (N)	Fruit, kernel, twig	Decoction is taken orally	2-phytosterol, parinarium, sterols A and B
Neocarys macrophylla (Neuroli tree)				
Rubiaceae	Kasfiya (H) Nambi	Root, twig, stem	Decoction is taken orally	Crossoptine pholobaphine, B-
Crysopteryx febrifuga	sunsun (N) Ayeye (Y)	bark, leaf		quinovine
Rubiaceae	Tafashiya (H) Gbashi (N)	Root, fruit, stem	Decoction is taken twice	Naufoline, augustine indole
Nuclea latifolia (African peach)	Egbesi (Y)	bark	daily	quinolizidine

Rutaceae Citrus aurantifolia (Sour orange)	Lemun tsami (H) Afofanta (I) Lemu bakagi (N) Orombo wewe (Y)	Leaves	Decoction is taken; steam from the decoction can be inhaled	Flavonoid, ascorbic acid
Rutaceae Citrus paradise (Grape fruit)	Furuntu (H) Oromo orji (I) Furuntu (N) Lemi iba (Y)	Fruits	Fruits are decocted and taken orally	Vitamin C
Rutaceae Zanthoxylum zanthoxyloides (African satin wood)	Fasa kwabri (H) Kosonkori (N) Ata (Y)	Root, stem	Decoction is taken as required	Zanthoxylol (antisickling) inulin, alkaloid, vanillic acid
Solanaceae Physalis angulata (Goose berry)	Matsar mama (H) Putu (L) Alasagi (N) Koropo (Y)	Whole plant	Decoction is taken as needed	Alkaloids, glycosides, inulin, saponin
Sterculiaceae Sterculia setigera	Kukuki (H) Eso funfun (L) Kokongiga (N)	Stem bark, seed	Decoction is taken thrice daily with hot water	Tannins, rhamnase, galactosylase
Sterculiaceae Theobroma cacao (Cocoa tree)	Cigban koko (N)	Seed	Decoction of dry seed is taken	Theobromine
Sterculiaceae Waltheria indica	Harkufa (H) Arkufe (N) Ewerepo (Y)	Whole plant	Cold water infusion or decoction is taken daily	-
Ulmaceae Trema orientalis (Charcoal tree)	-	Stem bark, leaf, twig	Decoction or infusion taken orally	Saponins, tannins, inulin

Zingiberaceae Curcuma longa (Turmeric)	Turi (N)	Rhizomes, fruits	Decoction is taken with milk or sugar	d-sabinene, aneol, borneol zingiberene D-phellandrene
Zingiberaceae Zingiber zingiber Syn: Zingiber officinale (Ginger)	Tsita maiyatsi (H) Tsutafu (N) Atale (Y)	Leaves, rhizomes	Rhizome is chewed raw; leaf decoction is taken thrice daily	Gingerol, phellandren, zingiberene, bisabolene, oleoresin
Verbenaceae Lantana camara	-	Fruits, leaves	Make tea with either fruit or leaves and take	Lantadene (toxic)
